Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns, Resource Utilization, and Cost of Care in Medicare Beneficiaries Newly Diagnosed with Acute Myeloid Leukemia and Treated with Venetoclax-Based Regimens

Joshua A. Roth, Paul G D'Amico, Alexander Russell-Smith, Simon Purcell, Elizabeth Donckels, Joseph C. Cappelleri, Jia Ma, Allison Petrilla, Jerry Kagan, Anthony Yu

Blood (2024) 144 (Supplement 1): 5191.

https://doi.org/10.1182/blood-2024-198239

Published: 2024

Journal Articles

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Kathy Annunziata, Nikoletta Sternbach, Hitomi Tanaka, Marco DiBonaventura, Joseph C. Cappelleri, Jack Watkins, David Hughes, Aster Meche, Chai Hyun Kim, C. Todd Kennedy, Hans Scheurer, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2024-201802

Published: 2024

Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek

Blood (2024) 144 (Supplement 1): 3367.

https://doi.org/10.1182/blood-2024-206951

Published: 2024

Journal Articles

Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)

Martin K. Kortüm, Sebastian Theurich, James Farrell, Joseph C. Cappelleri, Olivia Ashman, Shanti Neff-Baro, Aline Gauthier, Khalil Jewiti-Rigondza, Christof Scheid

Blood (2024) 144 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2024-204074

Published: 2024

Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

Charis Charalampous, Shaji Kumar, Ricardo D. Parrondo, Saurabh Chhabra, Madhu Nagaraj, Mei Sheng Duh, Priyanka J. Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Rickard Sandin, Joseph C. Cappelleri, David Hughes, Guido Nador, Marco DiBonaventura

Blood (2024) 144 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2024-204005

Published: 2024

Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek

Blood (2024) 144 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2024-206856

Published: 2024

Journal Articles

Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment

Hui Lu, Jenny Whitty, Travis Gould, Carmine Colavecchia, Josh Coulter, Nicola Dunn, Pratima Chowdary, Lisa J Wilcox, Joseph C. Cappelleri, Stephanie A Christopher, Alexis Sohn, Brett Hauber

Blood (2024) 144 (Supplement 1): 2591.

https://doi.org/10.1182/blood-2024-207425

Published: 2024

Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte

Blood (2024) 144 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2024-203723

Published: 2024

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek

Blood (2023) 142 (Supplement 1): 2015.

https://doi.org/10.1182/blood-2023-186409

Published: 2023

Journal Articles

Changing Care Journey for Patients with Multiple Myeloma in the United States

Darcy R Flora, Rachel Byrd, Daniel Platt, Patrick Hlavacek, Erinn Hoag Goldman, Joseph C Cappelleri, C Todd Kennedy, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2023-179554

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek

Blood (2023) 142 (Supplement 1): 6731.

https://doi.org/10.1182/blood-2023-185920

Published: 2023

Journal Articles

Multiple Myeloma Treatment-Related Decision-Making and Preferences of Patients and Care Partners in the United States

Darcy R Flora, Rachel Byrd, Daniel Platt, Patrick Hlavacek, Erinn Hoag Goldman, Joseph C Cappelleri, C Todd Kennedy, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 7357.

https://doi.org/10.1182/blood-2023-180951

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada

Isha Mol, Yannan Hu, Fiorella Fanton-Aita, Phu Vinh On, Hicham Gonzalez, Richard LeBlanc, Donna Reece, Jiandong Su, Engin Gul, Alissa Visram, Joseph C Cappelleri, Haitao Chu, Guido Nador, Patrick Hlavacek

Blood (2023) 142 (Supplement 1): 6738.

https://doi.org/10.1182/blood-2023-186559

Published: 2023

Journal Articles

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Gabriel Tremblay, DBA, MSc, BS, Patrick Daniele, Mike Dolph, MSc BHSc, Timothy J. Bell, Geoffrey Chan, MD, Andrew Brown, PhD, Joseph C Cappelleri, PhD MPH, MS

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137641

Published: 2020

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Bradley Mason, Carla M. Mamolo, PhD, Chloe Johnson, Andrea Viqueira, MD, Adam Gater, Alexander Russell-Smith, Sophi Tatlock, Richa Shah, PharmD, RPh, Joseph C Cappelleri, PhD MPH, MS

Blood (2019) 134 (Supplement_1): 5918.

https://doi.org/10.1182/blood-2019-123444

Published: 2019

Journal Articles

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Youngmin Kwon, BA, Timothy J Bell, MHA, Caitlyn Solem, PhD, Joseph C Cappelleri, PhD MPH, MS, Courtney Johnson, MPH, Helen Bhattacharyya, PhD, Caroline J. Hoang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2610.

https://doi.org/10.1182/blood-2019-126672

Published: 2019

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia

Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Ruth Mokgokong, Athina Palaka, Robert K. Hills, MA, DPhil, MSc, Nicholas Latimer, PhD, Bart Heeg, PhD

Blood (2018) 132 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2018-99-110800

Published: 2018

Journal Articles

Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carla M. Mamolo, PhD, Arlene Reisman, Andrew G Bushmakin, Joseph C Cappelleri, PhD MPH, MS, Rocco J. Crescenzo, DO, FACOI, Liza DeAnnuntis, Andrea Viquiera, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2018-99-110152

Published: 2018

NARROW

Real-World Treatment Patterns, Resource Utilization, and Cost of Care in Medicare Beneficiaries Newly Diagnosed with Acute Myeloid Leukemia and Treated with Venetoclax-Based Regimens

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Changing Care Journey for Patients with Multiple Myeloma in the United States

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Multiple Myeloma Treatment-Related Decision-Making and Preferences of Patients and Care Partners in the United States

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia

Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only